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This study investigated the anti-tumoral mechanism of a combination therapy 
using a DNA vaccine fused to the chemokine MIP-3α, IFNα, and 5-Aza-2’-deoxycytidine 
in the B16F10 murine melanoma model. Previous data from our laboratory showed 
enhanced survival in mice treated with this combination therapy, and tumor lysate 
expression revealed significantly upregulated levels of the chemokine CCL19. Flow 
cytometric analysis revealed enriched numbers of both vaccine specific and overall 
CD8+ T cells, as well as the percentage of CD3+ T cells that were CD8+. To further 
define the protective mechanism elicited by this combination therapy, we challenged 
female C57BL/6 mice subcutaneously with B16F10 melanoma, and treatment began 5 
days later. The vaccine was given intramuscularly by electroporation, with CpG C given 
intramuscularly two days later at the same site. IFNα was given intratumorally, and 
5Aza was given intraperitoneally. Expression of immunologically relevant proteins in the 
tumor lysate was evaluated by qRT-PCR, and flow cytometric analysis was used to 
analyze tumor-infiltrating lymphocytes (TILs), dendritic cells (DCs), and NK cells. In line 
with previous results, we saw reduced tumor sizes in the triple therapy group. Flow 
cytometric analysis of tumor tissue for this group confirmed previous CD8+ T cell data 
and indicated increased numbers of DCs and NK cells. Furthermore, the number of 
CD8+ T effector memory cells were also significantly increased in the combination 
group. Analysis of tumor lysate also revealed significantly upregulated CXCL13 
expression. Additionally, this study also aimed to clarify the role of age and sex in 





were treated with either vaccine and CpG C (CpG given simultaneously or two days 
later), CpG alone, or left untreated. Results revealed significantly smaller tumor sizes in 
females across all groups, in agreement with the literature.  
Results from this study suggest that the protective mechanism elicited by the 
combination therapy group involves the generation of tertiary lymphoid structures (TLS), 
which have been implicated as a positive prognostic factor in many cancers. However, 
more experiments, including immunohistochemical staining, must be conducted in order 
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1A. Melanoma   
Globally, cancer is the second leading cause of death, and resulted in 
nearly 9.6 million deaths in 2018. Many of these deaths (over 70%) occurred in 
low/low-middle income countries with preventable cancers forming a significant 
number of these cases (1). In the United States, there are expected to be 1.9 
million incident cases of cancer in 2021, with over 600,000 deaths. Of these 
cases, over 100,000 cases will be attributed to melanoma and around 7000 
people are expected to die from the disease (2). Melanoma is a skin cancer most 
common in the white population; the lifetime risk of acquiring the disease is 
“2.6% for whites versus 0.1% for Blacks, and 0.6% for Hispanics” (3). While the 
risk rises with increasing age, melanoma is quickly becoming one of the most 
common cancers in the younger population, especially for those between the 
ages 35-64 (3). The fatality rate for melanoma tends to be higher than those of 
other skin cancers (such as squamous cell carcinoma) because it has a higher 
likelihood of metastasizing to other parts of the body. The metastasis is often the 
cause of serious illness and death. The 5-year survival rate for stages I and II is 
over 95%, but later stages have poor survival and high mortality (4).  
Treatment for melanoma is dependent on the stage of the cancer; zero 
stage cancer (melanoma in situ), where the cancerous area is restricted to the 





area, but some doctors may also use topical creams such as imiquimod and 
radiation (these treatments are rare). First stage cancer, defined by the growth of 
the melanoma, is also treated by surgery but the excision is often wide and can 
include the skin around the tumor. Additionally, a doctor may also recommend a 
“sentinel lymph node biopsy” (SLNB) to scan the lymph nodes proximal to the 
tumor site for signs of metastasis – spreading of the cancer to secondary organs. 
If the biopsy finds cancer cells, lymph node removal and/or therapy with an 
immune checkpoint inhibitor or other targeted drugs is an option. For stage two 
melanoma, surgery for removal is still performed but as metastasis to nearby 
lymph nodes is more likely, an SLNB is often recommended. If cancer is 
confirmed, the route of therapy is similar to that mentioned for first stage cancer. 
In stage three, the cancer is already present within the lymph nodes upon 
detection and thus, surgical removal and adjuvant treatment with checkpoint 
inhibitors and targeted therapy drugs is routine. However, additional therapies 
including administration of the T-VEC (talimogene laherparepvec) Vaccine, 
bacille Calmette-Guerin (BCG) vaccine, Interferon alpha (IFNα), or Interleukin-2 
(IL-2) directly into the melanoma are also possible; so are radiation therapy and 
imiquimod cream. The last stage of melanoma, stage four, is diagnosed when 
the metastasis is pervasive – the melanomas are present within the distal lymph 
nodes and/or other organs. The skin tumors and lymph nodes are often excised 
by surgery and treated with radiation; the metastases of internal organs may or 
may not be removable by surgery. Those that cannot be excised are treated with 





those include checkpoint inhibitors and BRAF/MEK inhibitors (5,6,7). BRAF/MEK 
inhibitors include drugs such as vemurafenib and are a part of targeted therapy in 
melanoma. Of the patients presenting with advanced melanomas, nearly 50% 
have a mutation in the BRAF kinase, where the valine is substituted for a 
glutamine (104). The use of BRAF and MEK inhibitors have shown rapid 
antitumor responses, but these responses are often short lived due to tumoral 
resistance (105). While surgery presents few side effects, administration of 
immune checkpoint inhibitors requires careful monitoring of the patient as these 
drugs can cause serious adverse reactions. These therapies primarily include 
anti-PD 1/PD-L1 (anti-programmed death 1) and anti-CTLA 4 (anti-cytotoxic T 
lymphocyte antigen-4) antibodies that act on T cells that have been rendered 
ineffective by the tumor microenvironment. Since these antibodies act on all T 
cells expressing PD-1 and CTLA-4, the effects are felt throughout the body and 
include severe nausea, hepatitis, neurotoxicity and myocarditis (6,7). When 
combined with the use of targeted drug and/or chemotherapy, the side effects 
are amplified and can prove debilitating for the individual – often requiring 
hospitalization, as they can be fatal. Similar effects are seen with the 
administration of IL-2, as well as with BRAF/MEK targeted therapy (106).  
1A1. Cancer Vaccines  
Thus, a treatment that minimizes the side effects while maximizing 
chances of remission is urgently needed. Vaccines against cancer have 
historically been unsuccessful; only two licensed cancer vaccines exist on the 





(discussed in detail later) – and while they are commercially available, they 
are often implemented as a last resort (8,9). T-VEC is used in the melanoma 
setting, particularly for late-stage metastatic melanoma unresponsive to first 
line treatments. Provenge was created based on our knowledge of dendritic 
cells as potent T cell activators; while its exact mechanism of action is 
unknown, it works primarily by stimulating T cells via APCs bearing the PAP 
antigen, which is highly expressed in a majority of prostate cancer cells. It is 
most often used in cases of advanced prostate cancer that are resistant to 
hormone therapy (10,11).  
The mechanism of T-VEC’s action is an oncolytic virus – a virus 
engineered to kill cancer/tumor cells. Here, the herpes simplex virus, type 1 
(HSV-1) is engineered to express human granulocyte-macrophage colony-
stimulating factor (GM-CSF), and works primarily by selectively replicating in 
tumor cells and inducing host immunity. It is injected intratumorally and used 
in cases of advanced melanoma (11,12). A recent review (11) characterized 
the efficiency of T-VEC in treating advanced melanoma based on available 
literature and current clinical trials; in a phase II trial involving patients with 
stage III and IV melanomas, a response rate of 46.1% was noted in patients 
that received the T-VEC intratumorally. Additionally, an evaluation of a Phase 
III trial comparing the efficacy of intratumoral T-VEC vs GM-CSF  
(granulocyte-macrophage colony-stimulating factor) (the OPTIM trial) 
delivered subcutaneously in 436 patients presenting with stage III and IV 





16.3%, whereas GM-CSF was 2.1%.  Similarly, the overall response rate 
reflected a similar trend with T-VEC at 26.4% and GM-CSF at 5.7%. T-VEC 
also showed better responses regarding lesion reduction (11). Furthermore, 
the review also compared T-VEC efficacy with other approved melanoma 
treatments based on 4 clinical trials – the OPTIM trial, two ipilumumab trials 
(anti-CTLA-4), and 1 vemurafenib (BRAF inhibitor) trial. These last three trials 
involve checkpoint inhibitors and targeted therapy (BRAF inhibitors). Overall, 
T-VEC maintained a significant lead for survival cures when compared to the 
checkpoint inhibitors – especially for advanced melanomas. It is important to 
note that while the results are impressive, these analyses were conducted 
across studies and to show true dominance, a randomized comparative trial 
featuring the therapies must be performed (11). One of the main agents 
present in the vaccine, GM-CSF is a cytokine involved in promoting anti-
tumoral immunity, but research has indicated that its role maybe more 
ambiguous than expected as it may instead promote tumor growth as well 
(11). A literature review examining the role of GM-CSF when administered to 
advanced melanoma patients in clinical trials analyzed 26 studies; most 
studies used GM-CSF as an adjunct to other therapy including surgery, 
peptide vaccines, chemotherapy, etc. No benefit was observed when GM-
CSF was used in combination with the peptide vaccines, but the study found 
“some clinical benefit” in patients who received GM-CSF as an adjuvant in the 
other settings. However, it is important to note that flu-like side effects were 





dosing varied across different settings and studies. This review indicated that 
further studies are clearly required to better define the anti-tumoral role of 
GM-CSF (13).  
Another recent review summarized that the anti-tumoral role of GM-CSF 
was prominent only when dendritic cells (DCs) were directly involved – as in 
the case of T-VEC (14). Of note, one study observed tumor growth of 
melanoma when GM-CSF monotherapy was utilized (15). In addition to these 
questions, its mode of delivery – intratumoral injection – is still uncharted 
territory for many medical professionals, which curtails its use in the hospital 
setting. Furthermore, as T-VEC comprises live oncolytic virus, there are 
biosafety concerns with injecting patients in an “open” area such as a doctor’s 
office – yet another barrier to more frequent implementation (12,13). 
Cancer vaccines remain a crucial topic of interest in cancer 
immunotherapy, with a few promising candidates in clinical trials, including 
cell-based vaccines such as GVAX, a GM-CSF gene-transfected tumor cell 
vaccine (16), virus-based vaccines (similar to T-VEC), and peptide vaccines 
(17). Additionally, advances in systems for optimizing vaccine delivery have 
also been made in the form of nanoparticles (17), but more research is 
needed to address gaps in the literature. Finally, “personalized vaccine” 
strategies have also gained momentum with the discovery of cancer 
neoantigens – novel antigens expressed by tumor cells that may provide 
enhanced immunogenicity compared to tumor associated antigens as they 





normal cells (albeit are more highly expressed on tumor cells), immune cells 
are programmed to ignore these signals in an attempt to avoid autoimmunity. 
This decreases their immunogenic potential and the strength of the 
antitumoral response. However, tumor specific antigens are capable of 
bypassing the issue of self-tolerance. Since they are only expressed on tumor 
cells, these antigens are often immunogenic and can stimulate an effective 
immune response.  
1A2. Interferon Alpha (IFNα) in Cancer Therapy 
In addition to vaccines and checkpoint inhibitors, another method of 
immunotherapy that has been utilized in the cancer setting is recombinant 
interferon alpha (IFNα). A barrage of studies over the years have evaluated 
the role of IFNα in a multitude of cancers including melanoma, and most have 
recorded potent anti-tumoral effects (20,21). IFNα bind its receptor, IFNΑR, 
and triggers anti-cancer activity through multiple pathways. Often, this occurs 
through potent regulation and enhancement of the immune response, 
particularly by augmenting DC responses against the tumors and eliciting a 
Th1 bias in T cells. Th1 T cells promote the proliferation of cell mediated 
immunity and CD8 cytotoxic T cells. This is especially important as Th1 or cell 
mediated immunity has shown to be of paramount importance in cancer, as 
these T cells have cytotoxic potential capable of actively killing cancer cells 
(22-24).  
Furthermore, IFNα2 has been evaluated in the context of melanoma at 





effects remain modest, but when used as an adjuvant, its benefits are 
augmented – it is also the only drug approved by the FDA as an adjuvant 
therapy. A study examined the positive potential of pegylated IFN α2b 
(pIFNα) when given weekly for up to 5 years in stage III melanoma patients 
and found significant improvement in relapse free survival (RFS) 3 years after 
initiation; however, other factors such as overall survival (OS) and metastasis 
free survival did not show any significant improvement. It is also important to 
note that median treatment adherence was 1 year – only 23% of the patient 
population opted to continue treatment into the 4th and 5th years (25). Overall, 
multiple studies have reported some level of benefit as seen by OS upon 
IFNα therapy, but these benefits depend on dosage, delivery method, and 
duration of treatment. Additionally, IFNα therapy or therapies that encourage 
a potent IFNα response have been shown to be effective in both murine and 
human models of melanoma (20-25) 
However, despite its benefits, IFNα shows a dose-dependent toxicity with 
high doses causing severe side effects affecting multiple organ systems and 
ranging from flu-like symptoms to more serious occurrences such as 
neurological disturbances and hepatoxicity. The systemic nature of these 
toxicities is attributed to the abundance of the IFNΑR receptor, which is 
present on a diverse number of cells within the body, and to the high binding 
efficiency of IFNα to its receptor which amplifies the responses – both 
negative and positive (26).  





The final arm of anti-cancer therapy often includes a chemotherapeutic 
drug. One such agent is 5 aza-2’-deoxycytidine (5Aza, Decitabine), a pan-
cancer drug that works as a DNA demethylating agent/methyltransferase 
inhibitor; it is given as an IV infusion, with dosage dependent on factors such 
as height and weight (27,28). 5Aza is incorporated into DNA where it 
interferes irreversibly with the activity of methyltransferases and specifically 
targets CpG methylated sites on DNA strands. In cancer, loss of DNA 
methylation is understood as an early event; reduced methylation of 
prominent genes such as H-ras and MYC is highly common in a multitude of 
cancers. However, increased DNA methylation has also been observed in 
many cancers – this is especially important when DNA methylation occurs in 
regions coding for tumor suppressor genes (such as p53), which disrupts the 
control of normal cell division and significantly enhances the chances of a 
dividing cell going rogue and potentially becoming cancerous. This belief was 
validated by various studies conducted in the early 2000s; in one study, 
methylation of at least 1 CpG island covering a tumor suppressor gene was 
present in over 80% of 600 primary tumor samples covering fifteen different 
cancers (28). This is one of the main rationales for using 5aza and other 
demethylating agents. Several experiments have shown reactivation of tumor 
suppressor function in cancers where the gene was silenced due to DNA 
methylation (29). The agent does not seem to show any particular specificity 






In a study focused on cutaneous melanoma, the researchers found that 
treatment with 5Aza enhanced recognition of melanoma antigens (including 
gp100) by melanoma specific CTL via upregulation of MHC Class I antigens 
(30). Additionally, another study found that 5aza promoted CD8 T cell 
infiltration, thus augmenting the antitumoral response (31).  
 1A4. Combination Therapies  
The various anti-cancer therapies mentioned above, including vaccines, 
targeted therapy, chemotherapeutic agents, and Type I IFN, have been 
investigated both as monotherapies as well in combination with each other. 
Often, the efficacy of cancer therapy increases significantly when a 
combination of agents is employed as multiple neoplastic mechanisms are 
targeted for maximal effect. Since resistance to therapy remains a hallmark of 
cancer, different types of therapies targeting different mechanisms result in 
the greatest anti-tumoral effect. This phenomenon is seen in practice in the 
clinic as well, where physicians use a multi-pronged approach against 
malignancies including chemotherapy, radiation, immune checkpoint 
inhibitors, and or surgery (32) 
For melanoma, the treatment options have been extensively recorded in 
the previous part of this chapter. However, late-stage melanoma, which 
involves extensive metastases, does not respond effectively to current 
intervention strategies, and has an inordinately high mortality rate (2). For this 
reason, targeting metastatic melanoma with combination therapy presents an 





immunotherapy and chemotherapy, including checkpoint inhibitors against 
PD-1 and/or CTLA-4 and chemotherapeutic drugs such as Dacarbazine (33). 
As mentioned above, combination therapies are successful in eliciting a 
multitude of antitumoral mechanisms. Multiple studies have validated this 
finding, including work by Lucarini et al, in which the researchers showed 
enhanced antitumoral efficacy of IFNα and 5aza in a melanoma model. In 
their study, the therapy increased the presence of CD8+ TILS while 
decreasing immunosuppressive myeloid cells and Tregs (34). Additionally, 
studies have also found benefit in combining chemotherapy, radiation, and/or 
small molecule inhibitors with cancer vaccines (35,36).  
1B. Tertiary Lymphoid Structures  
Tertiary lymphoid structures (TLS) are a relatively recent phenomenon in 
the cancer community. Also known as ectopic lymphoid structures/nodes (ELS; 
ELN), these “tissues” develop in non-lymphoid areas and have been recorded as 
closely resembling the topography of lymph nodes; they are comprised of 
lymphocytes (known as tumor infiltrating lymphocytes or TILs) as well as APCs 
such as follicular DCs, and their occurrence has been documented in a plethora 
of cancer types including colorectal cancer, melanoma, lung cancer, and breast 
cancer (37). Owing to the expanding number of studies investigating the role of 
TLSs in cancer, hypotheses regarding both their prognostic predictive value and 
immunotherapeutic potential have gained considerable momentum. A major 
focus of many studies in this area consists of deciphering the anti-tumoral role of 





(38). While the classical view of an efficient anti-tumoral response involves 
antigen presentation to B and T cells via DCs in secondary lymphoid organs 
(SLOs), studies found that these responses also occurred at the tumor site, 
within organized structures highly similar in both structure and function to SLOs 
(37,38).  
While not unique to cancer, TLSs have received critical attention from the 
oncology research community. Since they resemble SLOs, they also provide the 
classical structure for generating an effective anti-tumoral response. This is 
furthered by a barrage of studies observing positive correlations between the 
presence of TLS and higher chances of survival/remission in patients with 
various solid malignancies, suggesting that their anti-tumoral role may possibly 
be a pan-cancer occurrence (39-41). Mechanistically, TLS formation and function 
remain areas of research where more information is urgently needed; while a 
general idea of what is involved in setting up and maintaining these structures 
does exist, many of the specifics remain unelucidated. However, chemokines 
and various adhesion molecules have an undeniably critical role in both 
formation and maintenance of TLS, as well as in TIL recruitment, activation, and 
proliferation (40,42,45). Some of these chemokines and adhesion molecules 
include CCL19 and 21, critical for T cell and DC recruitment within SLOs, 
CXCL13, responsible for B cell recruitment, and addressins such as PNAd 
expressed by HEVs bordering these TLS. Regarding location, these structures 
can be present both within the tumor and/or proximal to the tumor; the former 





seem to be more common than intratumoral TLS, but the frequency can vary 
depending on the type of cancer and the tissue involved (42-44).  
In melanoma, TLS present an interesting phenomenon. The role of TLS in 
melanoma has only recently been touched on, and there is an urgent need for 
more data in understanding the specifics of anti-tumoral TLS function in 
melanoma. Of the studies that have focused on this topic, most conclude that the 
presence of TLS – especially in patients with metastatic melanoma – is a 
favorable prognostic factor indicative of enhanced survival and remission (45,46). 
However, an understanding of TLS composition regarding effective anti-tumoral 
cell types, and how TLS can be induced in melanoma to augment current 
treatment regimens remains an understudied area. Furthermore, while there is a 
consensus regarding the positive associations of TLS with enhanced survival, 
only a few studies in recent years have stressed the importance of the cellular 
components involved in TLS; the cell types involved in these structures have 
shown to play an important role regarding remission vs relapse in cancer 
patients. While it remains a nascent field, these findings stress continued 
investigation in order to develop a more holistic understanding of TLS function in 
melanoma.  
 1B1. Evaluation of TLS 
Understanding whether a TLS exists in a particular cancer type depends 
critically on the methods used to evaluate them. Ever since their discovery, 
deciphering cellular markers indicative of TLS formation have been of utmost 





cytometry, and histopathology. Since TLS closely resemble SLOs in their 
organization and cellular composition, a major focus is based on assaying for 
markers connected to SLOs; these include staining for CD20, CD4, and CD8 
in histopathology/immunofluorescence, checking gene expression of B-cell 
and T-cell related genes (such as bcl2 and IL-2), as well as using flow 
cytometry to further understand the distribution of cell types within the TLS 
(44-46) 
Arguably, one of the most critical elements of TLS function is high 
endothelial venule (HEV) expression. HEV are specialized venules present in 
lymphoid tissues – including secondary lymphoid organs – that provide the 
requisite scaffolding needed for lymphocyte entry and egress out of lymphoid 
tissue (47,48). They express 6-sulfosialyl Lewis X ligands (PNAd) that bind 
the receptor CD62L, which is present on lymphocytes and allows their 
capture and movement along vessels. A study characterizing the presence of 
HEV across a range of human solid tumors, including melanoma, found a 
significant correlation between the density of HEVs present in the tumors and 
tumor infiltrating CD3+ and CD8+ T-cells as well as CD20+ B-cells. 
Furthermore, the T cells involved were biased towards Th1 immunity, which 
has traditionally been implicated in effective anti-tumoral responses and 
cytotoxic effector functions (49). In line with HEV expression, heightened 
expression of genes related to lymphocyte homing are also critical indicators 
of TLS formation, as they support the presence of lymphocytes in the tumor 





CCL21, CXCL12, and CXCL13; CCL19 and 21 bind CCR7, which is present 
on naïve lymphocytes, and CXCL12 binds CXCR4, which has a role in B cell 
activation and recruitment. CXCL13, which binds CXCR5, has shown to play 
a critical role in lymphoid organogenesis and B cell trafficking, with studies in 
deficient mice indicating incomplete maturation of SLOs (44,45). A similar role 
has been noted for the CCL19/CCR7 axis. Additionally, lymphotoxin beta 
(LTβ) expression, mediated by activated B cells, has also been shown to 
sustain TLS formation by feeding into production of the aforementioned 
chemokines. In concert with this idea, multiple papers have attempted to 
delineate the most critical chemokines involved in this process; one study 
identified a “12 chemokine signature” indicative of TLS formation and further 
indicative of positive prognosis in melanoma. These genes included CCL19, 
21, and CXCL13 (46). Furthermore, in addition to lymphocytes, the presence 
of DCs – especially follicular DCs (fDC) and mature DCs – also plays an 
important role in both TLS formation and function (50,51). Follicular DCs are a 
subset of stromal cells present within B-cell follicles and germinal centers and 
enable effective B cell responses within germinal centers by virtue of antigen 
presentation and chemokine secretion (52). Their presence has been noted in 
multiple types of cancer and has been associated with a positive prognosis in 
most; DC associated markers such as DC-LAMP have shown to be 
upregulated in tumors having TLS, and high levels of DC infiltration also 





Thus, when testing for the presence of TLS, it is necessary to take all 
these factors into consideration. Since it remains a relatively novel field, there 
is little consensus on what defines the “gold standard” of TLS presence, 
however, certain characteristics, such as the presence of B and T cells and 
elevated levels of certain chemokines such as CCL19, are almost a 
requirement when making the case for presence of TLS formation. Therefore, 
evaluating a model for TLS formation must involve testing for the factors 
mentioned in this section – often by multiple methods including qRT-PCR, 
flow cytometry, and histopathology/immunofluorescence.  
1C. B16F10 Murine Melanoma Model 
In mice, one of the most used melanoma lines is B16F10, a metastatic 
cancer cell line derived from female C57BL/6 mice. It presents a well-established 
and well-studied system in which treatment is extremely challenging. 
Furthermore, it is considered an accurate model for human melanoma, and thus 
is an effective model for translational studies (53,54). For the subcutaneous 
model, a lethal challenge of B16F10 cells (usually 1x105 cells/mouse) is injected 
subcutaneously into the mouse, and tumor growth is observed within 5-10 days 
of challenge, with the tumor measuring 1 cm3 by 14-21 days. Without treatment, 
after 21 days, the tumors often become necrotic, which, due to humane 
considerations, requires euthanasia (53). Mice also possess homologues of 
melanoma antigens expressed in humans including glycoprotein 100 (gp100), 





been utilized in various studies aiming to promote antitumoral responses in 
melanoma and therefore present appropriate targets for therapy (55).   
 1C1. Age and Sex as Variables in the B16F10 Tumor Model 
The B16F10 tumor model recently has focused predominantly on young, 
female C57BL/6 mice; however, sex differences play an important role in 
progression of the tumor, as well as the immune responses against it. It has 
been noted that female mice fare better when injected with tumor cells (either 
subcutaneously or intravenously), as seen by slower tumor growth and a 
slower rate of metastases. The reasons behind these phenomena have only 
recently begun being elucidated; Dakup et al noted significantly lower tumor 
volume and growth rate in females compared to males, and upon 
investigation found a higher number of CD4+ and CD8+ T cells in females – 
corresponding to effective antitumoral responses associated with smaller 
tumor sizes (56).  
Data on the effects of age, however, seem to be more conflicting. One 
study reported that older mice show delayed tumor growth (57), whereas 
another study investigating the metastatic model claimed that while lung 
metastases occurred earlier in older mice, the overall tumor growth was 
slower when compared to the younger cohort (58).  
Overall, the limited literature in this subfield clearly indicates age and sex 





work is needed to further clarify these discrepancies and the reasons that 
underlie them.  
BACKGROUND 
In this study, a DNA vaccine fused to the chemokine MIP-3α and 
expressing the melanoma antigens Gp100 and Trp2 was given to C57BL/6 mice 
in combination with IFNα and 5Aza following lethal subcutaneous challenge with 
B16F10 tumor cells. Previous studies from our laboratory have demonstrated 
superior efficacy of the antitumoral response of this combination therapy as seen 
by significantly lower tumor size and increased survival (56). Results revealed 
enriched T cell and DC populations in the combination group, and interestingly, 
extremely elevated levels of CCL19 expression. This study aimed to clarify the 
nature of the antitumoral response initiated by the combination therapy. Based 
on results from previous experiments, especially those showing enhanced 
expression of CCL19, and current literature in the field, it was hypothesized that 
this robust antitumoral response may occur by way of tertiary lymphoid 
structures, a phenomenon associated with a positive prognosis in many cancers 
including melanoma. Additionally, age and sex as variables affecting tumor 
progression in response to treatment were also investigated. 









Investigating the Anti-Tumoral Mechanism of an Immature Dendritic Cell 
Targeting Vaccine in Combination with 5-Aza-2’deoxycytidine and IFNα in the 
B16F10 Murine Melanoma Model 
2A. Introduction  
Cancer immunotherapy has already undergone a remarkable evolution in 
the last few decades. The discoveries of Interferon, T cells, DCs and NK cells 
were critical in describing their emerging role in controlling cancer, and more 
recent studies have built on these initial findings to solidify the indisputable role of 
the immune system in eradicating tumors (93, 94). The most recent 
advancements in this field include cancer vaccines and checkpoint inhibitors 
(94). Checkpoint inhibitors (ICB) such as anti-PD-1 and anti-CTLA-4 have shown 
good efficacy in a multitude of cancers, especially in those impervious to other 
modes of therapy such as radiation and/or chemotherapy. Their mechanism of 
action directly targets inactivated/exhausted T cells by engaging the regulatory 
molecules CTLA-4 and PD-1, which are upregulated on activated T cells and 
lead to a reduction in their capability to control and eradicate tumors. Checkpoint 
inhibitors block the ability of these molecules to interact with their respective 
ligands, thus allowing T cells to retain their activated phenotype and mount an 
effective anti-tumoral response (95). However, despite its efficacy, ICB 
administration is accompanied by a significant number of side effects that can 
prove to be debilitating (95). Furthermore, while there is increased survival in 





These issues have motivated more research into other kinds of 
immunotherapies, including those focused on cancer vaccines and antigen 
presenting cells (APCs). Only two cancer vaccines have been licensed for clinical 
use – the T-VEC vaccine and Sipuleucel-T (PROVENGE). Both vaccines use 
different platforms, with the former using an oncolytic virus and the latter being a 
cellular vaccine focused on the ex vivo expansion of a patients’ APCs, especially 
DCs (10,12). The encouraging safety and efficacy data for cancer vaccines has 
spurred more research into this field, especially in the arena of DCs.  
In the tumor microenvironment (TME), DCs play a critical role. They are 
the most efficient activators of the T cell response, and the cDC1 subset of DCs 
is capable of cross-presentation, allowing them to prime CD4+ and CD8+ T cells 
simultaneously (96). DC activation occurs by of engagement of Toll-like receptors 
(TLRs), and different DC subsets present differential TLR expression. 
Historically, IFNα administration as cancer treatment represented one of the first 
pillars of immunotherapy. Today, IFNα is still a licensed cancer treatment that, 
when combined other types of treatments, shows enhanced antitumoral efficacy 
(34). These results led to the belief that the type 1 IFN response played an 
important role in triggering effective immune responses in the TME, especially 
those involving T cells. There is extensive literature documenting the role T cells 
play in controlling and eradicating tumors (97,98), and their efficient activation 
with tumor antigens is an undeniably important step in the antitumoral response. 





antigens, break them down into epitopes, and present them via MHC II pathways 
(cDC1, pDCs, cDC2) or both MHC I and MHC II (cDC1). 
The initiation of the adaptive immune response depends largely on the 
ability of APCs to uptake antigen and present it to lymphocytes, therefore, 
therapies that enhance this uptake could potentially show increased antitumoral 
efficiency. This understanding of the critical role of DCs in the initiation of the 
adaptive immune response led our laboratory to create a DNA vaccine encoding 
antigens overexpressed on melanoma cells, Trp2 and Gp100, fused to the 
chemokine ligand 20 (CCL20), also known as Macrophage Inflammatory Protein-
3 (MIP-3α). CCL20 binds chemokine receptor 6 (CCR6), a receptor present 
primarily on immature DCs (iDCs) (99). Previously published results indicated the 
enhanced immunogenicity of this vaccine in comparison to one expressing a 
defective MIP3a fusion, as well as one fused to a non-melanoma antigen (35). 
Furthermore, previous studies also confirmed that type 1 IFN responses were 
important in conferring enhanced survival, and to augment these results, direct 
administration of IFNα was added to the treatment regimen, and CpG C, a known 
TLR9 agonist and stimulator of Type 1 IFN responses, was chosen as the 
vaccine adjuvant. Finally, based on the promising potential of combination 
therapies when employed with cancer vaccines (34), the common chemotherapy 
agent 5-aza-2’deoxyctidine (5aza) was also added to the treatment. 5aza is a 
methyl transferase inhibitor that has been shown (119) to overcome inhibition of 
expression of IFN responsive genes that occurs by methylation, overcoming 





combination treatment – vaccine, IFNα, and 5aza – showed doubled median 
survival time and the smallest tumor sizes compared to the negative control. 
Cellular analysis of the combination group revealed significantly enriched 
populations of CD3 T cells that were CD8+, as well as the overall numbers of 
CD8+ T cells per mm2 of tumor. Furthermore, CD8 T cell presence was also 
significantly correlated with reduced tumor size, underscoring their critical role in 
the TME (35).  
To further understand the immune responses involved in the triple therapy 
group, a transcriptome analysis of immune response-related genes was run on 
the mRNA isolated from the tumor lysate. Results revealed significantly 
upregulated levels of CCL19, and its expression was 68-fold higher in the triple 
therapy group than in the IFN+5Aza alone group. Similar to the CD8 T cell data, 
higher levels of CCL19 were also correlated with a reduced tumor size (35). 
Chemokine ligand 19 (CCL19) functions primarily as a homeostatic chemokine in 
secondary lymphoid organs. As a homeostatic chemokine, it is responsible for 
the recruitment of immune cells into SLOs by binding CCR7, its receptor (59). 
CCL21, sister chemokine to CCL19, shares this phenotype as well. However, 
research suggests roles for CCL19 beyond the recruitment of CCR7+ immune 
cells. Importantly, it has been implicated in the formation of tertiary lymphoid 
structures (TLS), which are lymphoid aggregates that form ectopically in a 
multitude of pathological settings including cancer (37). Research regarding TLS 





prognostic factor indicative of an effective antitumoral immune response 
(37,38,40).  
Finally, other parameters that remain largely unexplored in the B16F10 
melanoma mouse model are age and sex. The fact that immune responses are 
significantly impacted by these two variables is now a conclusive finding in most 
oncology research; however, the literature detailing the specific responses in the 
context of the B16 melanoma is still scarce. A few studies (56-58) have detailed 
some of these impacts, but overall, there remains much to be explored in this 
arena. To begin addressing the gaps in the literature, this study also piloted a 
small experiment aiming to understand the impact of age and sex in the B16F10 
melanoma model. For sex differences, older female and male mice (10-14-
weeks-old) were given either vaccine and adjuvant simultaneously, vaccine and 
adjuvant two days later, adjuvant alone (CpG C), or were given no treatment. 
The no treatment group was used to understand the differences in natural tumor 
progression whereas the other groups were utilized to understand differences in 
responses to therapy. Based on those limited studies, we hypothesized that 
female mice, despite being older, were likely to outlive the male mice and have 
slower tumor growth. To understand the impact of age, we used data from 
females given vaccine and adjuvant two days later and compared them with data 
from a previous experiment utilizing 6-8-week-old female mice given the same 
treatment. Here, we hypothesized that older female mice would show slower 





Our cumulative findings, especially the marked enhancement of CCL19 
expression, led us to hypothesize that the formation of TLS may contribute to the 
enhanced survival observed in the triple therapy group. The current study aimed 
to explore this hypothesis by evaluating TLS formation in the triple therapy group 
by way of flow cytometry and qRT-PCR analysis. Furthermore, as age and sex 
have been identified as important variables impacting the immune response, this 
current study also aimed to explore the variations in tumor growth and 
differences in response to therapy between male and female mice, as well as 
young and old female mice.  
2B. Results  
2B1. Tumor Size Differences between Administered Therapies 
This current study covered two different experiments, and tumor size 
measurements were taken for both.  
First, to understand potential differences in tumor growth and response 
to treatment mediated by sex differences, 10-14-week-old male and female 
C57BL/6 mice were used. Mice were subcutaneously challenged with a lethal 
dose of B16F10 melanoma cells (5x104), and tumor sizes were measured 
every 1-3 days using automated calipers. Mice were challenged on day 0, 
and vaccinated (if indicated) on days 5, 12, and 19; adjuvant was given on 
days 7, 14, and 21 (if indicated). The no treatment group was used to 
compare differences in tumor growth between older male and female mice, 





differences in delivering vaccine and adjuvant simultaneously v/s adjuvant 
given 2 days post vaccination. Two groups given adjuvant at two different 
timepoints were utilized as previous data from the laboratory indicated 
greatest production of cancer antigens 2 days post vaccination; in order to 
validate this finding and explore any possible differences, vaccine and 
adjuvant were also given simultaneously to a separate group of mice. 
Statistical analysis of these differences was performed using a 2-way ANOVA 
or a mixed effects model if the data did not meet the assumptions of the 
ANOVA. Results indicated that across all groups, including no treatment, 
female mice had significantly smaller tumors (Fig. 1a-d), and some statistical 
significance was established between male and female mice. Group II 
females (those receiving vaccine and CpG separately) also saw the longest 
survival (euthanized day 30) relative to the other groups. Importantly, males 
across all groups were euthanized by day 23. Interestingly, for the males, 
vaccine and adjuvant given simultaneously (Group I) worked more efficiently; 
the average size of tumors for Group 1 were around 150 mm2 (Fig. 1e) and 
differences between the therapy and no treatment were highly significant (p = 
0.0003). The group given vaccine and CpG C two days later had an average 
tumor size of 250 mm2, also significantly different compared to the no 
treatment group (p = 0.0369) (Fig. 1b). Overall, female mice saw significantly 
smaller tumors and responded better to therapy – especially to vaccine and 
CpG C given two days later (Fig. 1b). These findings also validated previous 





treatment, tumor sizes from older female mice utilized in this experiment were 
compared to a previous experiment involving 6-10-week-old female C57BL/6 
mice (Fig. 1f). Since only Group II (vaccine and CpG given 2 days later) was 
consistent across the two experiments, it was the only one used for analysis. 
A 2-way ANOVA revealed no significant differences between older and 
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Second, tumor sizes were evaluated in the TLS experiment in the same 
manner. For this study, 6-10-week-old female C57BL/6 mice were utilized and 
challenged the same manner as mentioned above. This experiment also included 
administration of IFNα and 5Aza (if indicated). Results from this study 
corroborated previously published data as tumor sizes in the triple therapy group 
were the smallest (Fig. 2a); it is important to note that due to the low power of the 
experiment, statistical significance could not be established between groups for 
this experiment, but the combination of 3 experiments including the current study 




Fig. 1. Tumor size variability based on age and sex differences. a-d) Differences in tumor growth in older 
female mice v/s older male mice; these data represent one experiment with n = 3 F and 2 M per group. Each 
graph stratifies the differences between males and females based on the treatment indicated: a) Vaccine + CpG 
given simultaneously, b) Vaccine + CpG given 2 days later, c) CpG alone, and d) no treatment. e) Differences in 
tumor growth between groups for male mice; same experiment as a-d. f) Differences in tumor size between older 
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 2B2. Tumor Lysate Gene Expression 
Since previous results indicated enriched levels of CCL19 and the role of 
the type 1 IFN response in enhancing survival in the combination group, 
additional genes related to these scenarios were chosen for transcriptional 
assessment. As the sister chemokine to CCL19, CCL21 was the first gene 
evaluated. Since both bind CCR7 and share a largely redundant phenotype, it 
was hypothesized that CCL21 expression was most likely to mirror CCL19 
Fig. 2. Tumor growth in response to therapy. Vaccine was given intramuscularly on days 5, 12, 
and 19 post challenge, IFNα was given subcutaneously at the tumor site and 5Aza was given 
intraperitoneally opposite to the tumor site. Panel a) depicts the data from one experiment and b) 





expression. However, surprisingly, this was not the case. CCL21 expression was 
not upregulated to the same extent between the treatment groups, and neither 
was there any correlation between its presence and tumor size (Fig. 3a and b). In 
order to explore this in further detail, we focused on genes involved in the 
upregulation in CCL19. This led us to genes related to the Type 1 IFN pathway, 
as interferon related genes have been implicated in CCL19 expression 
(100,101). Six genes were chosen for this panel and included IRF3, IRF9, IFNB, 
IFNΑ, RelB, and MB21D1 (Fig. 3c). All primers were purchased from Applied 
Biosystems, and qRT-PCR was run on late timepoint RNA extracted from 
previous experiments. Gene expression was highly variable across all candidates 
and no genes were either significantly upregulated or downregulated for any 
particular group.  
Based on these results, we then tested for genes related to TLS formation. 
As CCL19 has been found to be significantly upregulated in solid tumors 
presenting with TLS, we assessed the expression of two genes, CXCL13 and 
CD62L/LSEL. Both genes have are involved in TLS formation; CXCL13 is a 
chemokine responsible for B cell trafficking into SLOs by binding CXCR5 (102), 
and CD62L is an integrin upregulated on lymphocytes capable on “rolling” on 
high endothelial venules (HEVs) (49). Both lymphocytes and HEVs have been 
implicated as critical components of TLS (35,49,102,103). CXCL13 expression 
was significantly upregulated in the triple therapy group, especially in comparison 
to IFN + 5Aza (Fig. 3d), and its presence was also significantly correlated with 





as ΔCt values; for the FED, both the vaccine and the triple therapy group were 
compared to IFN + 5Aza alone whereas ΔCt values were compared across all 
groups. Based on FED and ΔCt values, LSEL/CD62L was also upregulated (Fig. 
3f) and was significantly upregulated in the combination group when compared to 
IFN + 5Aza. However, there were no significant differences between vaccine 
alone and the combination group. 
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 2B3. Tumor Infiltrating Lymphocytes, DC, and NK Analysis  
To understand the immune makeup of the TME, flow cytometric 
analysis was performed on tumor tissue. Prepation of tumor cells, staining, 
and gating were performed as indicated in sections 2C3 and 2C4. First, the 
presence of DCs was evaluated. The log tranfsformed counts of overall 
Cd11c + cells and Cd11c CD8a+ cells were significantly upregulated in the 
combination therapy group, and %Cd11c cells that were CD8α+ were 
trending higher in the combination group relative to both vaccine and 
IFN+5aza (Fig. 4a). Importantly, this same subset of cells was also correlated 
with reduced tumor size, as indicated by an R2 of 0.33, albeit with a trending p 
value (p = 0.067) (Fig. 4b). These results align with previous published (36) 
and unpublished results. Since this experimental model involves IFNα and 
Fig. 3. qRT-PCR analysis of tumor RNA. a) Fold expression difference of CCL21 relative to the 
IFN+Aza group (outliers removed) and b) Correlation between CCL21 -dΔCt values and tumor size. 
CCL21 expression was analyzed for 3 independent experiments and correlation for 1. n = 3 - 5 mice per 
group. c) Fold expression of six candidate genes (IRF3, IRF9, IFNB, IFNΑ, RelB, and MB21D1) relative 
to IFN+Aza expression. n = 3 mice per group, data from 1 experiment. d) – f) Fold expression and ΔCt 
values of two candidate genes (CXCL12 and LSEL) were analyzed; for FED, analysis was performed 
using the IFN+Aza group as the comparator. n = 3 mice per group, data from 1 experiment. e) 









previous results stressed the role of type 1 IFN responses in conferring 
protection, this study also aimed to clarify the presence of pDCs. pDCs, when 
activated, produce large amounts of IFNα and can activate CD8+ T cells 
without CD4+ T cell help.  While not significantly different between groups, 
pDCs were elevated in the triple therapy group (p = 0.0972). T cell inflitration 
into the TME was also evaluated in the same manner as DCs. In this panel, 
CD8+ T cells (CD3 CD8+) were examined to ensure reproducability of 
previously published data, and the CD8+ memory effector (Tem) population 
was evaluated based on its critical antitumoral role. Similar to DCs, the log 
transformed numbers of both CD3+CD8 T cells and Tem T cells (CD3+CD8+ 
CD62L-CD44+) were signficantly upregulated in the combination group 
relative to IFN+5aza (Fig. 4c) with a p <0.05, and the memory subset was 
significantly upregulated compared to vaccine as well. Additionally, both T cell 
subsets were also highly correlated with reduced tumor size, as indicated by 
an R2 of 0.5729 and a p = 0.0113 for CD8 T cells, and an R2 of 0.8146 and a p 
= 0.0004 for the effector memory subset (Fig. 4d).  
In contrast to both DCs and T cells, staining for B cells in the tumor 
tissue did not yield similar results. B cells were evaluated for infiltration into 
the TME using B220 and CD19 as B cell markers. While the analysis 
revealed no significant differences in the CD19+ population between 
treatment groups, B220+CD19+ double positive B cells were significantly 





Furthermore, there was no correlation between CD19+ cell positivity and 
reduced tumor size (Fig. 4f).   
Last, in addition to the other cell types, NK cells were also evaluated 
for presence in the tumor tissue. NK1.1 was used as the marker for NK cells. 
Analysis revealed a significantly higher population in the combination group 
compared to vaccine alone as well as an upwards trend compared to 
IFN+Aza group (Fig. 4g). NK cell infiltration was also significantly correlated 
with reduced tumor size (Fig. 4h).  
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Fig. 4. TILs, DC, and NK analysis. a) Flow data showing log transformed numbers of CD11c and 
CD11c+CD8a+ cells, as well as percentage of CD11c+CD8a+ cells. b) Correlation between CD11c+CD8a+ cells 
and tumor size. Data from 1 experiment, n= 3 mice per group. c) Flow data showing log transformed numbers of 
CD3+ CD8 T cells and Effector Memory CD8 T cells, as well as percentage of CD3+ cells that are CD8+ T cells, 
and percentage of CD3+CD8+ T cells that are CD62L- and CD44+. d) Correlation between the two T cell 
subsets and tumor size; n = 3 mice per group and data from 1 experiment. e) Flow data showing log transformed 
numbers of both B220 and CD19 DP B cells as well as CD19+ B cells. f) Correlation between CD19+ cells and 
tumor size; n = 3 mice per group and data from 1 experiment. g) Flow data showing log transformed numbers of 








  Age and Sex Experiment 
10–14-week-old female and male C57BL/6 mice (Charles River 
Laboratories, Wilmington, MA) were challenged subcutaneously in the left 
flank on Day 0 with 5x104 cells B16F10 tumor cells (>95% viability, volume 
of 100 µl). Tumor size was taken every 1-3 days (units recorded were 
square mm); endpoint analyses were to assess differences in tumor 
growth and survival between males and females. Mice were kept in the 
study until they died or had to be sacrificed. Conditions for humane 
sacrificing of the mice included tumor size exceeding 20 mm, tumor tissue 
necrotizing, and significant lethargy (59). 
  Combination Therapy Experiment  
6–10-week-old female C57BL/6 mice were challenged in the same 
manner as for the age and sex experiment. Tumor size was recorded 
every 1-3 days in square mm, and endpoint analyses were to assess 
presence and/or differences in TLS formation in the group receiving the 
vaccine, IFNα, and 5Aza. The same criteria for sacrificing mice were used 
in this experiment as mentioned above.  
2C2. Vaccine Design, Vaccination, and Therapeutics  
  2C2i. Plasmid Design 
The plasmid utilized for this vaccine was a modified pCMV vector 
(36) and encoded the mouse melanoma antigens gp100 and trp2 fused to 





mouse IP-10 was also included. The plasmid was extracted from DH5-a E. 
coli using Qiagen Endo-Free Plasmid Maxi and Giga kits. Post extraction, 
vaccine purity was measured by Nanodrop spectrophotometry and gel 
electrophoresis, and the sequence was confirmed by restriction enzyme 
analysis as well as complete DNA sequencing. Restriction enzyme 
analysis included enzymes XhoI and XbaI (NE Biolabs).  
  2C2ii. Vaccinations  
Extracted DNA was diluted in 1x endo-free PBS at 1 mg/ml, and each 
mouse received a 50-µg dose intramuscularly (volume of 50 µl) in the right 
tibialis. Each vaccination was followed by in vivo electroporation. Pulses 
were delivered with an ECM 830 Electro Square PoratorTM with 2-Needle 
ArrayTM Electrode (BTX Harvard Apparatus®; Holliston, MA) using the 
following parameters: 106 V; 20 ms pulse length; 200 ms pulse interval; 8 
total pulses. Based on previous published data, CpG C (ODN2395) was 
also given intramuscularly as an adjuvant at the same dosage and site; it 
was also diluted to 1 mg/ml in 1x endo-free PBS. The vaccine was given 
at days 5, 12, and 19 post challenge, and adjuvant was given 2 days after 
each vaccination.  
2C2iii. Therapeutics  
Two additional therapies (if indicated) were also utilized. These 
included Recombinant Mouse Interferon Alpha-A (IFNα) and 5 Aza 2’-





(10,000 units) followed by 3 days of low doses (1000 units), whereas 5aza 
was given intraperitoneally at 1 mg/kg. Both therapies were given as 50 µl 
volume to each mouse at the described timepoints as indicated in Supp. 
Fig. 4.    
2C3. Lymphocyte and Tumor Infiltrating Lymphocytes Isolation (TILS) and Flow 
Cytometry 
  2C3i. Lymphocyte Isolation – Spleen  
Cell suspensions of each were made under sterile conditions by 
grinding harvested tissue with pestles and filtering them through sterile 60 
uM mesh filters. The suspensions were spun down at 4 deg C, 250 g for 7 
minutes, and spleens were processed by the addition of ACK lysis buffer 
to lyse RBCs (1 ml/spleen, incubated at RT for 3-5 mins) and washed with 
sterile PBS (20-30 ml to stop lysis); cells were spun again at the same 
settings and were either resuspended in sterile 1x PBS/FACS buffer for 
immediate staining or 4 ml freezing media/spleen for cryostorage.  
  2C3ii. TILs Isolation – Tumors  
Tumor suspensions were made by grinding tumor tissue with frosted 
ends of microscope slides, washing with sterile PBS, and filtering through 
sterile 60 µM mesh. ACK lysis buffer was also added to the tumor 
suspensions to lyse RBCs. Cells were resuspended in sterile 1x PBS and 
counted using a ZI Coulter Counter and used for subsequent staining.  





Tumor cells resuspended in 1x PBS were transferred to a 96 well V-
bottom plate and stained with a live/dead (L/D) stain (30 mins at RT in the 
dark) and washed with FACS buffer (0.5% BSA in sterile 1x PBS). 
Following L/D, cells were stained with a surface antibody cocktail (20 mins 
at RT in the dark) and read on the Attune NxT flow cytometer. Gating 
strategy was as follows: live singlets were gated based on L/D stain, and 
then were stratified based on the different stains used. For Panel 1, live 
singlets were sorted into B220+ cells and further separated based on 
expression on Cd11c and Gr-1 (pDC) and CD19 (B cells). For B220- cells, 
cells were selected based on NK1.1 expression (NK cells), as well as 
Cd11c and CD8a expression indicative of dendritic cells. For Panel 2, live 
singlets were sorted into CD3+ and CD3- populations. From the CD3- 
population, cells were gated on CD11c and CD8a expression (DCs). The 
CD3+ population was used to gate for T cells; it was further stratified into 
CD8+ cells. The CD3+ CD8+ gated population was analyzed for CD44 
and CD62L expression. A quadrant gate created for these populations, 
and the CD3+CD8+CD44+CD62L-population was also further gated for 
CCR7 expression. Flow data was analyzed using Flow Jo software and 
total cell counts were back calculated from tumor weight and volume of 
cells plated. Multiple panels were performed on the harvested tissue; 
tumors were stained to look for various immune cells as elaborated below.  





Stains used: B220-FITC, CD19-PECy7, Gr-1-APC, NK1.1-AF700, 
and CD11c-PE 
       2C4ii. Panel II – CD8+ T effector memory cells  
Stains used: CD3-PerCpCy5.5, CD8-FITC, CD62L-APC, CD44-
AF700, CCR7-PECy7, and CD11c-PE 
2C5. Gene Expression by qRT-PCR 
Gene expression was analyzed by qRT-PCR on RNA extracted from 
previous experiments (experiments were performed using the same parameters 
set in the current study) as well as the current experiment. RNA extraction was 
performed using Trizol, the high-capacity cDNA synthesis kit was used to reverse 
transcribe mRNA to cDNA, and gene expression was analyzed for the late 
timepoint. Probes used were GAPDH, CCL19, CCL21, RelB, IRF3, IRF9, 
MB21D1, IFNΑ, IFNB, CD62L, and CXCL13 and the procedure was performed 
using TaqMan Gene Expression Master Mix and TaqMan Gene Expression 
Assays. To calculate ΔCt, the Ct value of the gene of interest (e.g., CXCL13) is 
subtracted from the Ct value of the housekeeping gene (GAPDH). Similarly, ΔCt 
was calculated by subtracting the Ct values of the gene of interest from the Ct 
value of the IFN+5Aza group. Finally, fold expression difference (FED) was 
calculated by applying the following formula: 2(-ΔΔCt). Analysis was performed in 
Microsoft Excel.  





For tumor sizes, qRT-PCR, and flow cytometric analyses, a one-way 
ANOVA was used to test for significance. Tumor sizes taken at one time point 
were log2 transformed, and tumor growth was analyzed by two-way ANOVA 
when data were being compared across multiple time points. If the data were not 
uniform (e.g.: one group had only 3 mice whereas the others had 4), Mixed 
Effects Analysis was used instead of the two-way ANOVA which requires 
complete data uniformity. Scatter plot correlations between tumor sizes and 
markers of interest were analyzed by simple linear regression. All data was 
stored in Microsoft Excel, and Prism Graphpad 9 was used for both statistical 
analyses and creation of figures. For all datasets, the significance level was set 

















3A. Age and Sex as Variables in the B16F10 Melanoma Model  
Historically, age and sex as variables affecting the immune response have 
largely been disregarded in the research setting; only recently have questions 
surrounding these variables gained traction and received a great degree of 
interest from the oncology community. As previous studies with our B16F10 
subcutaneous melanoma model have been consistently performed in 6-10-week-
old female C57BL/6 mice, the current study aimed to understand and expand on 
any possible differences in tumor progression, response to treatment, and 
survival between male and female mice, as well as young v/s older female mice.  
3A1. Sex Differences  
To determine sex differences, twenty 10-14-week-old female and male 
C57BL/6 mice were separated into 4 groups; Group I received the vaccine 
and adjuvant simultaneously, Group II received vaccine alone with adjuvant 
given 2 days after vaccination, Group III only received adjuvant, and Group IV 
received no treatment; each group consisted of 3 females and 2 males. All 
males had to be euthanized by day 23 as they had surpassed the set 
thresholds. Importantly, both males in the no treatment group were 
euthanized on day 17, whereas the females in the group were euthanized on 
day 21. As Group IV received no treatment, this group was used as a marker 





studies (56-58) have indicated that tumor progression is slower in females 
compared to males and our pilot study aligns with these findings. However, 
since the power of the experiment remained small, the experiment will have to 
be repeated in order to confirm these initial observations.  
Additionally, this study design also aimed to clarify the response 
generated by CpG C, the adjuvant. Previous experiments from our lab have 
utilized CpG C based on the prominent involvement of IFNα in the antitumoral 
response (59) and the observation that CpG C is a potent activator of IFN 
related immune responses (82). However, the efficacy of CpG C alone in this 
model had not been evaluated; this is important as studies by others have 
indicated an antitumoral response attributed to singular therapy with CpG C 
(78). Therefore, to clarify the extent of CpG C’s involvement in the immune 
response, Group III was treated with adjuvant alone; CpG was given 
intramuscularly on days 7, 14, and 21 post challenge at the same dosage (50 
µg, volume of 50 µl) into the right tibialis. On day 21, both males and one 
female were euthanized as their tumors had surpassed 20 mm2 in diameter, 
and the remaining two females were euthanized on day 23. These data, 
especially in the females, potentially indicate that while CpG C does provide 
some level of protection, it is relatively modest. Thus, the boost in survival we 
see with the vaccine and CpG C is not solely attributable to adjuvant alone – 
the combination of both is critical.  
 Furthermore, previous published results from our lab showed greatest 





thus, adjuvant was administered 2 days post vaccination to maximize effect. 
This study aimed to replicate those findings by comparing the antitumoral 
efficacy of vaccine and adjuvant delivered simultaneously (Group I) v/s 
adjuvant given 2 days post vaccination (Group II). Group II females had the 
smallest tumor sizes (Fig. 1b); on day 23, Group II females had an average 
tumor size of 161 mm2 whereas Groups I and III (CpG alone) were 268 mm2 
and 336 mm2 respectively (Fig. 1a, 1c). Furthermore, in males, there were no 
clear differences between the two groups – Group II males were euthanized 
on day 19 and Group I males were euthanized on day 21, and both had 
similar tumor sizes (Fig. 1e).  
Overall, the results from this pilot study seem to align closely with the 
existing literature. Female mice showed slower tumor growth when compared 
to males, as seen by longer survival and smaller tumor sizes. Additionally, 
these results also provide evidence for the marginal role of CpG C in this 
tumor model when given as a single therapy, as the tumor sizes and survival 
rates between the no treatment group (Group IV) and adjuvant alone were 
similar and not significant. Furthermore, the decision to deliver adjuvant 2 
days post vaccination was also vindicated by these findings as Group II 
females displayed the smallest tumor sizes and the longest survival time 
overall. However, to confirm statistical significance, more experiments need to 
be performed in the future. 





In addition to examining the role of sex, this experiment also aimed to 
understand the impact of age in the B16F10 tumor model. It is important to 
note that this analysis was only performed using female mice. In order to 
perform this analysis, tumor sizes and survival were measured for the current 
experiment and compared to a previous experiment. 10-14-week-old female 
mice receiving vaccine and adjuvant 2 days later were compared to an earlier 
experiment involving 4-6-week-old female mice receiving the same therapy. 
In order to maximize consistency during the comparison, only tumor sizes 
measured on the same days were used; a 2-way ANOVA was performed on 
the data for analysis and revealed no significant overall differences between 
the two age groups (Fig. 1f). While limited by sample size, this initial 
observation was interesting; while some literature has implicated age in 
slower tumor growth (58), many of these studies have simply evaluated 
growth in response to no treatment. Since this comparison involved a 
previous experiment, a no treatment group was not available for comparison 
– thus, it will be critical to evaluate whether there are differences in tumor size 
between older and younger mice when not given any treatment. Furthermore, 
it is also important to understand how our other therapies will influence this 
observation, and whether older males respond differently compared to 
younger males; this is especially important as the tumor growth was highly 
robust in older males, and no significant differences were observed between 






The immune responses underlying these potential differences must also 
be investigated; Dakup et al (56) indicated that female mice had a higher 
infiltration of CD8+ T cells compared to males, which was critical for a 
stronger antitumoral response. However, there are few studies examining 
these differences – it is important to understand how different therapies (such 
as chemotherapy and immunotherapy) differentially impact female and male 
mice. In humans, men are diagnosed with melanoma at a higher rate than 
women, and also have a slightly higher mortality rate (2,3). Interestingly, data 
indicates that recent immunotherapies have shown better efficacy in men 
than women. Both phase I and II trials on ICB showed that while both men 
and women benefitted from treatment, men showed a significantly greater 
level of response (120). According to our results, tumors in the older male 
mice grew faster compared to the females, not allowing enough time for the 
vaccine to establish anti-tumor immunity. In our model, treatments were given 
either 5- or 7-days post challenge, but it may be worth investigating whether 
earlier treatment of males may yield different results; since the tumors grow 
faster, earlier treatment could potentially allow for the generation of an 
antitumoral response in time. Furthermore, it would also be important to see if 
the initial results seen from the ICB therapy trials would apply to our therapy 
with 5aza and IFNα. Ultimately, there is minimal literature available on the 
impact that age and sex have on the natural progression of tumor lines such 
as B16F10, as well as the differences in response to various cancer 





further elucidate the observations made in this pilot study. This is especially 
important as the 10-14-week-old mice used in the study are not completely 
analogous to the older human population.  
3B. Combination Therapy with an Immature DC Targeting Vaccine, IFNα, and 5aza, and 
its role in TLS Formation 
3B1. The Role of CCL19 
Previous work in our lab utilizing the same experimental model revealed 
upregulated levels of CCL19 in all therapy groups, with the highest 
upregulation seen with vaccine, IFNα, and 5aza therapy. Furthermore, 
regression analysis revealed a tight correlation (Sup. Fig 1) between high 
levels of CCL19 and smaller tumor size. CCL19 is a “homing” chemokine 
responsible for trafficking CCR7+ immune cells and lymphocytes into the 
lymph node and is important for facilitating productive adaptive immune 
responses within SLOs. CCL21 also binds CCR7, and as a consequence of 
binding the same receptor both chemokines have a number of redundant 
functions involving immune cell recruitment to SLOs. While CCL19 is 
secreted by mature DCs, CCL21 is primarily secreted by the endothelium of 
afferent lymphatic vessels, whereas HEVs and stromal cells secrete both. 
However, a few studies have attempted to outline differences between the 
two; specifically, it has been noted that CCL19 is the only chemokine known 
to trigger robust phosphorylation and internalization of the B arrestin receptor, 
which leads to more effective antigen presenting DC and CD4+ CD8+ T cell 





and thus more available to the local environment. Many of these functions 
have been elucidated using plt mice, which are deficient in both CCL19 and 
CCL21, as well as ccr7-/- mice. These differences seem to be stressed in our 
findings as well, since qRT-PCR analysis of tumor tissue revealed no 
consistent expression pattern or correlation between CCL21 and tumor size 
(Fig. 2a and 2b). In the context of immune responses however, the 
differences between CCL19 and 21 remain controversial. While both are 
homing chemokines, some studies report CCL21 as being more important for 
T cell and DC migration (63), whereas others confer equivalent roles in DC 
and T cell activation. This role is especially critical in the context of this study 
as a higher influx of CD8α+CD11c+ DCs was seen in the combination group 
(although not significant), and CD8+ T cells were significantly upregulated in 
the same group that also showed the highest expression of CCL19 – Group 
III (Fig. 4). Importantly, Marsland et al observed that CCL19 did not directly 
activate T cells – as seen by the inability of naïve T cells coincubated with 
CCL19 to become activated – and thus, all T cell proliferation occurred by 
way of DC maturation. Furthermore, CCL19 also upregulated co-stimulatory 
molecules CD40 and CD86 as well as cytokines IL-12 and IL-1β in DC, 
significantly enhancing their ability to engage and activate T cells. DCs 
activated with CCL19 also preferentially induced Th1 licensure in T cells, as 
seen by significantly higher levels of IFNγ producing cells compared to a 
decrease in IL-4 producing cells. Additionally, the activation of DC in plt mice 





of MHC II but showed significantly lowered levels of co-stim molecules CD80 
and CD86 (63). In a 2011 study by Haessler et al, the differences between 
CCL19 and 21 regarding their ability to attract DCs in a 3D microenvironment 
was investigated. Their results indicated equivalent migration of DCs towards 
both cytokines at small gradients, but more efficient migration towards CCL21 
at a higher gradient, as well as when CCL21 and CCL19 were both present in 
the system (62). In contrast, a more recent study by Hansen et al noted a 
different finding; they showed that human monocyte derived DCs migrated 
more potently towards CCL19 than CCL21. Additionally, they concluded that 
autocrine CCL19 signaling by DCs negatively impacted their migration 
towards CCL21 with differences in potency being the deciding factor (64). In 
our model, we see elevated levels of overall CD11c DCs and CD8α+CD11c 
DCs in our combination group, which is critical since they are a 
proinflammatory subset of DCs capable of cross presentation and 
consequently activating both CD4 and CD8 T cells. These findings, together 
with the observation that CCL19 is a robust DC licensor and that those DCs 
preferentially activate Th1 T cells, may help explain the robust anti-tumoral 
response in the combination group.  
As noted in the Results, CCL21 expression was not as upregulated as 
CCL19. These results were surprising since both bind the same receptor and 
share a multitude of functions. However, reviews focused on CCL21 in 
melanoma have noted conflicting results (107). In certain studies, CCL21 is 





is corelated with a stronger immune response, especially regarding CD8+ T 
cell recruitment into tumor sites (107-109). CCL21 is also known to activate T 
cells by upregulating CD4 and CD8 expression and encouraging a Th1 bias in 
activated T cells (108). Furthermore, multiple studies evaluating TLS in 
melanoma often report CCL21 overexpression (108). However, in a study by 
Shields et al., tumor secreting CCL21 in the B16 melanoma model facilitated 
the development of an immunosuppressive TME by increasing Tregs and 
MDSCs, whereas CCL21 deficient TMEs promoted greater anti-tumoral 
immunity (110). Conversely, a group using a DNA vaccine encoding Trp2 in 
B16 melanoma found that CCL21 was an effective adjuvant that enhanced 
Trp2 specific immunity; however, timing was critical, and the protocol was 
only effective when CCL21 was given 24 h prior to the vaccine, at the same 
site (111). As expected, the tumor specific immunity was dependent largely 
on cell mediated immunity, which CCL21 is known to stimulate. Similarly, 
another study examining the role of CCL21 secretion by melanoma cells 
found that high CCL21 expression via a ubiquitin promoter resulted in 
massive immune infiltrates of CD4 and CD8 T cells, as well as CD11c+ DCs, 
and complete rejection of CCL21 positive melanomas within 3 weeks (109). 
Importantly, in melanoma, the CCL19/CCL21/CCR7 axis is known to 
contribute to increased metastatic potential, and high expression of CCR7 is 
associated with poor prognosis (112). In one study, overexpression of CCR7 
in B16 melanoma cells increased metastatic potential of the tumor, while 





(113). Additionally, CCL21 has also been shown to be involved in TLS 
formation, where many solid tumors presenting with TLS also show an 
increase in CCL21 expression (46). Since TLS are often correlated with better 
prognosis, this presents another scenario where heightened levels of CCL21 
in the system indicate a strong immune response. Ultimately, there are 
conflicting data on the role of CCL21 in melanoma. In some situations, CCL21 
is associated with immune events that favor a strong antitumoral response 
whereas in others, its presence is related to a tolerogenic TME and poor 
prognosis. More research is needed to understand what exactly drives these 
differing responses and how they can be manipulated to create a strong 
antitumoral immune response.  
 3B2. The impact of TILs, DCs, and NK cells 
Th1 T cells are key enactors of cell mediated immunity, which has been 
touted as being critical to an effective anti-tumoral response. Multiple studies 
across multiple types of malignancies have validated this belief (65-67), and 
often, a shift from Th2 biased responses to Th1 responses marks an upward 
trajectory in terms of an effective response – as seen by tumor regression 
and disease remission (68). CD8+ CTLs possess active killing ability; it is 
their successful activation which shapes an effective anti-tumoral response 
(69,70). Our results showed significantly elevated levels CD8+ T cell numbers 
and higher levels CD8α DCs in our combination therapy model, and their 
presence correlated strongly with reduced tumor size (Fig. 3 and 4). 





anti-cancer immunity is the CD8+ effector memory subset (Tem). These T 
cells are characterized by the loss of CCR7 and CD62L and maintenance of 
CD44, allowing their dissemination from SLOs and trafficking into distant 
tissues where their presence is required. Importantly, Tem cells possess lytic 
activity and can kill cancerous cells; they have reduced activation 
requirements compared to their naïve counterparts and persist for a long time 
(71). Increased levels of CD8+ T cells and CD8 memory T cells have been 
correlated with positive prognosis in multiple cancers (72-74), and our results 
confirm these observations as both effector CD8 T cells and CD8 Tem were 
highly correlated with a reduced tumor size (Fig. 4d). In a previous 
experiment, the presence of CD4 T cells was also evaluated, but the numbers 
remained relatively unchanged over the different treatments (Supp. Fig 2) and 
were not correlated with a reduction in tumor size.  
Unlike T cells however, B cells did not show the same trends. Surprisingly, 
the CD19+ B cell population was highly reduced in the combination therapy 
group and showed no correlation with reduced tumor size (Fig. 4e and f). 
Multiple studies over the years have delineated the anti-tumoral role of B cells 
in the B16F10 melanoma model, and studies in human melanomas have 
paralleled the same findings (75-77). Interestingly, in one such study, B cell 
depletion in mice using an anti-CD20 antibody resulted in significant 
impairment of Tem and Teff populations (78); however, in our model, we saw 
enriched populations of both CD8 T cells and CD8 Tem cells in the 





decrease in B cells was noted over two experiments (Fig. 4e and Supp. Fig 3) 
and the same trend was noted in both. In addition to CD19, B220 was also 
utilized as a pan B cell marker – the same trend was noted with B220+ 
CD19+ B cells (Fig. 4e). It is important to note that most studies focused on 
identifying B cells in TLS use the marker CD20 as opposed to CD19; while 
there is no reason to suggest that CD19 expression can be downregulated on 
B cells, future work will focus on utilizing a CD20 marker instead. Overall, our 
results present an interesting contrast to the literature as our combination 
therapy model shows enhanced survival without significant CD19+ B cell 
infiltration and seems to depend on T cell and DC infiltration instead.  
Since there was an enrichment of B220+ cells in the combination group 
that did not correspond to B cells, flow cytometry using anti-CD11c, anti-Gr-1, 
anti-NK1.1, anti-B220, and anti-CD35/21 was performed to further classify the 
B220+ and B220- CD19- subset. Results revealed enrichment of an NK 
population (NK1.1+) in the combination group that was tightly correlated to 
reduced tumor size (Fig. 4g and h), as well as an upward trend in 
plasmacytoid DCs (pDCs) (B220+Gr-1+CD11c) between the vaccine and 
combination groups (p = 0.0972, Fig. 3a). Both NK cells and DCs have been 
implicated in anti-tumoral immunity, but research regarding pDCs is has 
produced conflicting results (79,81). In melanoma, pDCs often promote an 
immunosuppressive environment – a function which contrasts with their ability 
to preferentially activate Th1 T cells via production of type 1 IFN, as well as 





(79). Importantly, while their presence in melanomas has historically been 
correlated with poor patient outcome, regressing tumors have enhanced 
presence of activated pDCs capable of producing type 1 IFN, which is a key 
function that is lost in pDCs isolated from progressing melanomas (79,80). 
Furthermore, pDC activation occurs via the engagement of TLR7 and TLR9, 
and stimulation with their agonists has shown to induce type 1 IFN production 
by pDCs present in the TME – as seen by the response generated by topical 
application of imiquimod to superficial basal carcinomas (81). This finding was 
replicated by the intratumoral injection of CpG-ODN (a TLR9 agonist) into 
murine melanoma, where systemic T cell immunity was dependent in part on 
successful pDCs activation (82). This observation was furthered by the fact 
that intratumoral injection of “blood-derived CpG-activated pDCs” successfully 
elicited NK cell and cDCs activation, which were then critical to the induction 
of tumor specific T cells (82). These findings may be highly relevant in the 
context of our model as we injected IFNα intratumorally (if indicated) (and 
intramuscularly in a previous publication, which showed similar effectiveness) 
as a series of 1 high dose followed by 3 low doses, as well utilizing CpG C as 
our vaccine adjuvant. CpG C is a potent TLR9 agonist known to stimulate 
pDC activation both in vitro and in vivo; this combination may be critical in 
providing a boost to poorly activated pDCs, which could then engage in the 
productive cross talk of activating T cells – a phenomenon we observe 





indicate significant differences in pDC levels between groups, these findings 
warrant further study.  
NK cells also form a critical component of this antitumoral immune 
scaffolding; these cells play an essential role in the immunosurveillance 
regarding cancer, and their lethal activity is often inactivated by cancer cells 
using a wide variety of mechanisms (83-85). Furthermore, NK cell infiltration 
into tumors has been correlated with better prognosis as well (86). Activation 
of NK cells often occurs by way of type I IFN; in vitro studies have shown NK 
cell activation as a result of cytokines such as IFNα and IL-12 secreted by 
mature DCs (87,88), and reciprocally, activated NK cells are also capable of 
activating DCs and augmenting tumor specific T cell responses (89,90). This 
is especially important in our model as NK cells, like pDCs, can also be 
activated by type 1 interferons and/or TLR7/TLR9 agonists. Since we see 
enriched populations of both NK cells and DCs in the combination group that 
are correlated with a reduced tumor size, it is highly possible that this 
crosstalk plays a critical anti-tumoral role in this system – especially since 
these productive, bidirectional responses are tightly involved with T cell 
activation (91) and may involve colocalization of DCs and NKs. Interestingly, 
there is also evidence that a strong presence of DC-NK cell crosstalk may be 
enough to bypass the role of CD4 T cells in CTL induction (92). This may 
represent an important finding, as in our model, CD4 T cell counts were not 
significantly upregulated in any group and did not show the same trends as 





 3B3. Potential TLS formation   
In addition to its role in DC migration, maturation, and subsequent T cell 
activation, the CCR7/CCL19/CCL21 axis is critical to both maintenance and 
function of SLOs; thus, its possible role in the formation and function of 
tertiary lymphoid structures has also been hypothesized (40,42). TLS are 
lymphoid aggregates resembling SLOs that form ectopically and have been 
observed in a multitude of pathologies including infectious diseases, 
autoimmune disorders, and cancer (40-42). They share significant similarities 
in both structure and function to SLOs, including the presence of APCs such 
as DCs and macrophages, as well as B and T cells. Because CCL19 is 
responsible for homing CCR7+ immune cells into the lymphoid follicle, its 
expression has been consistently noted in solid tumors displaying TLS 
(42,46); furthermore, when compared to tumors without TLS, CCL19 
expression is significantly upregulated in those tumors displaying TLS as 
confirmed by IHC. Although TLS function in cancer is a continuously evolving 
topic of research, many studies across different types of cancer seem to 
agree that the presence of TLS in solid tumors presents a prognostic 
advantage (40-46). Since our results indicated a combination of factors 
involved in TLS (increased T cells, DCs, and CCL19 expression), we focused 
on identifying other factors strongly associated with TLS formation in 
melanoma. Like CCL19, another chemokine that is upregulated in tumors 
having TLS is CXCL13. CXCL13 binds its cognate receptor CXCR5, and is 





organization (114). In a study by Henry et al., CXCL13 blockade by antibody 
disrupted B cell organization within TLS, and another study focused on 
immunotherapy in melanoma (115) also noted that tumors presenting with 
TLS had upregulated expression of CXCL13. This same study also noted 
upregulated levels of CCL19 in TLS. Additionally, another critical component 
of TLS are high endothelial venules (HEV), which are distinct blood vessels 
that allow the entry and exit of lymphocytes from the periphery and into TLS, 
where they can interact with APCs and become activated (43,49). 
Lymphocytes express CD62L (also known as L-selectin), which binds the 
peripheral node addressing receptor (PNAd) present on the HEV. This 
interaction allows the extravasation of B and T cells and their subsequent 
interaction with APCs. In one study, the density of HEV was correlated with 
better patient outcomes in melanoma (116), in line with findings regarding 
TLS in melanoma also being a positive prognostic factor (56,38,42). Thus, 
based on these findings, we tested the tumor lysate for both CXCL13 and 
CD62L expression. As seen in Fig. 3d, when compared to the IFN+5Aza 
group, CXCL13 expression was significantly upregulated in the combination 
therapy group, and so was CD62L. Interestingly, for CXCL13, based on the 
ΔCt values, there were no significant differences between the combination 
group and vaccine only. This is most likely due to the high variance seen in 
the vaccine only group, whereas in the triple therapy group, the values were 
relatively clustered together. Another interesting thing to note is that CXCL13 





saw a significant downregulation of CD19+ B cells in our triple therapy group. 
In recent findings, however, CXCL13 has also been involved with T cells 
(114). Specifically, in a study by Silina et al. that focused on lung cancer, 
tumors with high CXCL13 expression were correlated with increased 
recruitment of CXCR5+ T cells into TLS, and better patient outcome (117). 
Another study reported that CXCL13 secretion induced by lysophosphatidic 
acid (LPA) resulted in increased CD3+ cell influx, which was ablated using a 
CXCL13 neutralizing antibody (118). Thus, these findings suggest that 
CXCL13 also has a critical role in T cell recruitment in addition to its role in B 
cell recruitment. In our model, CXCL13 expression was significantly 
upregulated in the triple therapy group, and this upregulation was highly 
correlated to reduced tumor size (Fig. 3e). Similar to CXCL13, CD62L 
expression in the combination group was also upregulated, albeit to a lesser 
extent, and there were no significant differences between vaccine and the 
triple therapy group (Fig. 3e). However, based on the ΔCt values, differences 
between IFN+5aza and the combination group were significant. As 
mentioned, CD62L on lymphocytes binds PNAd on HEV, which form a critical 
component of TLS. In our model, mice receiving combination therapy showed 
a significant increase in both CD3+CD8+ T cells, as well as Tem cells. While 
Tem cells have downregulated CD62L expression, naïve T cells and central 
memory T cells express CD62L. Our flow data indicated that a majority of T 
cells in the combination group are effector memory T cells, which are capable 





overall increase in CD8+ T cells in the combination therapy group correlates 
with the increase in CD62L expression seen in the same.  
CONCLUSIONS 
Combined, our current and previous data show an increased influx of 
DCs, NKs, and T cells, as well as upregulation of CCL19 and CXCL13. Thus, 
based on these findings, the mechanism of increased survival in the 
combination group may be through the formation of TLS. However, the 
studies performed are not sufficient to prove TLS presence and future studies 


















4A. Age and Sex as Variables in the B16F10 Murine Melanoma Model 
The murine B16F10 model is one of the most widely utilized models of 
melanoma in oncology research, and yet its implementation has primarily been 
limited to female C57BL/6 mice. There is a dearth of literature available on this 
matter, and so, this pilot study aimed to investigate both age and sex differences 
using a previously published experimental model involving a unique vaccine 
platform. Our results showed largely what the few published articles in the field 
have reported, especially regarding sex differences. Female mice lived longer 
and had overall slower tumor growth whereas tumors in male mice grew very 
robustly and remained largely unresponsive to treatment. It is important to note 
that these differences were limited to observation, and the power of the 
experiment was limited. For the future, it will be critical to repeat these particular 
experiments and possibly incorporate other scenarios as well. For example, this 
study did not compare age differences in male mice or differences in natural 
progression of the tumor between older and younger female mice. Additionally, it 
will be critical to parse the immunological phenomena governing these 
differences. Finally, as mentioned, 10-14-week-old mice are analogous to 30 
years of age in humans, which is not considered old. Thus, in order to make 
appropriate comparisons between older mice and older human beings, the mice 





4B. Combination Therapy with an Immature DC Targeting Vaccine, IFNα, and 5aza, and 
its role in TLS Formation 
Our unique combination therapy model involves administering a MIP-3α 
fused DNA vaccine, IFNα, and 5aza therapeutically post lethal subcutaneous 
challenge with B16F10 melanoma cells. In this group, we see significantly 
enhanced survival as well reduced tumor growth when compared to mice treated 
with either vaccine alone or only IFN+5Aza. In order to enhance our knowledge 
of an effective antitumoral response, it is critical to parse the immune interactions 
facilitated by the combination therapy; thus, this study aimed to understand and 
expand upon the cellular makeup of the TME and investigate whether the 
augmented survival could potentially be dependent on the formation of tertiary 
lymphoid/tertiary lymphoid - “like” structures. Our results corroborated previous 
findings and presented new data as well. Gene expression data also showed 
significantly upregulated levels of CXCL13 in the triple therapy group, another 
marker implicated in TLS formation. However, expression was only analyzed for 
one experiment, and in order to fully understand the significance of this 
observation, more experiments will be tested for expression. Additionally, while 
CD62L was used to approximate HEV expression, a PNAd marker will be used in 
the future to increase accuracy as PNAd is actively expressed on HEV. This 
experiment highlighted the critical role of CD8+ Tem cells in controlling tumor 
growth, as well as highlighting the possible critical role of NK-DC crosstalk in this 
particular therapeutic model. Furthermore, our work indicates the possibility of an 





and a focus instead on T cells, NK cells, and DCs. Future experiments will focus 
on classifying the enriched NK cell population in order to fully understand their 
role in the system, and staining the tumor tissue for presence of TLS, via markers 
such as CD3 and CD11c. We will also stain tumor tissue with a CD20 marker for 
B cells to compare any possible differences between CD19 and CD20 
expression. Most publications staining tumor tissue for TLS utilize CD20 as a B 
cell marker, thus it will be important to confirm that we truly do not see B cells in 
























Supp. Fig. 1. Correlation analysis between CCL19 -ΔΔCt levels and tumor size (mm2). Starred 
group represents the triple therapy/combination therapy group.  
Supp. Fig. 2. Effect of different treatments on CD4 expressing t cells/g of tumor. Flow data 













Supp. Fig. 3. Effect of different treatments on CD19 expressing B cells/g of tumor. Flow data 
showing number of CD19+ B cells per g of tumor.  
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